Deal facts
- Buyer
- Merit Medical Systems, Inc.
- Target
- Solo Pace, Inc.
- Deal value
- USD 45,000,000
- Announced
- 29 October 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Merit Medical Systems, Inc. acquired Solo Pace, Inc., a Minneapolis, Minnesota maker of temporary pacing technology, on October 13, 2026. Merit acquired all remaining outstanding equity of the company for purchase consideration of approximately $45 million. Merit announced the deal on October 29, 2026 in a press release furnished as Exhibit 99.3 to a Form 8-K, the same day it reported third quarter results.
Solo Pace's products are designed for transcatheter aortic valve replacement (TAVR) and other transcatheter heart valve procedures, where temporary pacing is used during valve deployment. The SOLO PACE CONTROL external pulse generator works with SOLO PACE FUSION, a single-use sterile kit for temporary intracardiac pacing that combines guide wire functionality, left ventricular pacing and patient grounding in one device. Solo Pace announced FDA 510(k) clearance of FUSION on April 17, 2025 and its commercial release on March 31, 2026.
Merit was not a new counterparty. Before the acquisition it was the exclusive distributor of Solo Pace's pacing technology and owned approximately 18% of the company. That stake came from agreements executed between January 2023 and December 2025, under which Merit paid a total of $5 million for Solo Pace shares, an option to acquire all remaining equity based on certain commercialization milestones, and exclusive distribution rights upon commercialization.
The 8-K states that the purchase was made under a Stock Purchase Agreement, with Merit paying cash. Merit said it used cash balances for the purchase consideration, which it estimates will cost approximately $1.5 million in lower interest income over the twelve months ending December 31, 2027. It projects the deal to be immaterial to its 2026 revenue and earnings per share. For 2027, Merit projects slight accretion to non-GAAP net income and earnings per share, excluding approximately $3.2 million of non-cash and non-recurring transaction-related expenses, but slight dilution on a GAAP basis. It expects GAAP accretion thereafter. Parr Brown Gee & Loveless served as Merit's legal advisor.
Deal timeline
1 update- CompletedClosed
Merit Medical Systems, Inc. completes acquisition of Solo Pace, Inc.
Item 2.02. Results of Operations and Financial Condition . On October 29, 2026, Merit Medical Systems, Inc. (“Merit”) issued a press release (the “Earnings Press Release”) announcing its operating and financial results for the quarter ended September 30, 2026. A copy of the Earnings Press Release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Item 7.01. Regulatio
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Merit Medical Systems, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive